January 21, 2022 05:16 AM ESTUpdated 01:17 PM

As Hal Barron steals the show, there’s no off position on the John Maraganore switch; Danny Bar-Zohar makes another leap forward at Merck KGaA

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Derek Graf

→ The needle on the Maraganore Meter is moving again, as John Maraganore keeps collecting more post-Alnylam roles. First, he and BeiGene co-founder Peter Ho …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As Hal Barron steals the show, there’s no off position on the John Maraganore switch; Danny Bar-Zohar makes another leap forward at Merck KGaA

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Derek Graf

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

As Hal Bar­ron steals the show, there’s no off po­si­tion on the John Maraganore switch; Dan­ny Bar-Zo­har makes an­oth­er leap for­ward at Mer­ck KGaA

Copy Chief

Editor

Sign up to read this article for free.

As Hal Barron steals the show, there’s no off position on the John Maraganore switch; Danny Bar-Zohar makes another leap forward at Merck KGaA